Financials
| Final Results | Apr. 01, 2022 |
| Half-year Report | Sep. 30, 2021 |
| Annual Financial Report | Apr. 15, 2021 |
| Final Results | Apr. 01, 2021 |
| Interim Results | Sep. 30, 2020 |
| Final Results | May. 26, 2020 |
| Interim Results | Sep. 30, 2019 |
Proxies
| Result of AGM | Jun. 28, 2022 |
| Result of AGM | May. 24, 2021 |
| Result of AGM | Jun. 30, 2020 |
| Result of AGM | Jun. 20, 2019 |
| Result of AGM | May. 26, 2017 |
| Result of AGM | May. 23, 2016 |
| Result of AGM | Jun. 29, 2015 |
Ownership Update
| Holding(s) in Company | Mar. 24, 2022 |
| Holding(s) in Company | Mar. 21, 2022 |
| Holding(s) in Company | Feb. 24, 2022 |
| Holding(s) in Company | Jan. 25, 2022 |
| Holding(s) in Company | Jan. 06, 2022 |
| Grant of Options | Jan. 04, 2022 |
| Holding(s) in Company | Dec. 07, 2021 |
Announcements
| Cancellation of admission to trading on AIM | Feb. 15, 2023 |
| Update on Administration and Suspension of Trading | Dec. 30, 2022 |
| Blautix Phase II Clinical Trial Results Published | Nov. 16, 2022 |
| MRx0518 SITC 2022 poster presentations | Nov. 10, 2022 |
| MRx0518 poster presentations at SITC 2022 | Oct. 05, 2022 |
| Update on Suspension of Trading on AIM | Sep. 29, 2022 |
| Publication of preclinical autism research | Aug. 24, 2022 |